Skip Navigation

This clinical trial will test the safety and efficacy of a treatment regimen of the remdesivir plus the anti-inflammatory drug baricitinib for COVID-19. It is the next iteration of NIAID’s Adaptive COVID-19 Treatment Trial (ACTT), which began on February 21, 2020 and evaluated Remdesivir. In this next trial called ACTT 2, all participants will receive remdesivir or remdesivir with baricitinib.

View the complete news release